Experience

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the controlling shareholder of Notre Dame Intermédica, of 54,000,000…

Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. RAPT…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its common stock for up to an aggregate amount of $125 million. Based…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion Therapeutics, Inc. of $250 million aggregate principal amount of…

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…

Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…

Davis Polk advised the representatives of the several underwriters in connection with the $258 million SEC-registered offering of 3,000,000 shares of common stock of Berkeley Lights,…

Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…

Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…

Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal amount of its 6.500% senior notes due 2025. The notes are…